At the news
? BULLISHIMPACT 7/10 8-K filed Apr 8, 2026 at 16:41 ET
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, for gynecologic cancers. The company plans to resume enrollment and provide a mid-year program update.
- FDA removed partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab
- Study evaluates lorigerlimab in patients with platinum-resistant ovarian cancer or clear cell gynecologic cancer
- To date, 41 patients have been dosed in the LINNET study
- Company plans to resume enrollment and provide mid-year 2026 update
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access